Protocols in Current Issue
Protocols in Past Issues
0 Q&A 9343 Views Aug 5, 2014
Hepatitis E virus (HEV) is one of the main causes of acute hepatitis worldwide. Infections are particularly severe in pregnant women and chronic hepatitis E is known to occur in immunocompromised patients. Current therapy (ribavirin or pegylated alpha interferon) has severe side effects and cannot be employed in all patients. In order to evaluate potential new inhibitors of HEV replication, a luminescence-based replicon assay is particularly useful since it offers a rapid read-out and does not pose any biosafety risks (Debing et al., 2014).

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.